The agency is proposing to reduce the production amount of five opioids, including oxymorphone, fentanyl, hydrocodone, hydromorphone and oxycodone, which were subject to greater scrutiny after the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act was passed last year.
Combined with morphine, the proposal would lead to a 53 percent decrease in the allowable amount of these opioids since 2016, according to Drug Topics.
Read the full report here.
More articles on pharmacy:
Florida compounding facility recalls all human and animal drugs for lack of sterility
Despite ‘Right-to-try’ law, drugmakers still prefer FDA review, GAO finds
Opioid settlements may mean big tax breaks for Big Pharma
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
